- BMSystems will participate to BIO in Boston, June 18-21; and Bio-Europe in Hamburg November, 12-14.
- Munich,may 11-12, 2012: BMSystems' CSO François Iris, is invited as session chairman to the 8th International Workshop on Computational Neuropsychiatry: Sleep, Affective disorders and Schizophrenia - An integrated view.
- Press-Release-Feb-2012: Pherecydes Pharma secures a €1.2-million Defense agency funding for evaluating the use of bacteriophages against infected, antibiotic resistant burns.
Downloads
BMSystems European Commission Conference Presentation
The EC "From Systems Biology to Systems Medicine" report
Industrial biotech World cluster
Spin-off sites
Business - Value Generation
BMSystems value Generation
- BMSystems is a research-based biotech company that creates CADI™ models to generate businesses with immediate applications through contract or collaborative research programs.
- BMSystems does not sell its technologies nor access to its technologies, but collaborates with its clients under adapted contractual frameworks to suite their requirements.
- BMSystems, thanks to its collaborative research strategy, can address with limited marketing costs all the markets (biomedical,chemistry, energy, environment, etc...) where its CADI™ models can generate strong competitive advantages for its clients and partners.
- BMSystems collaborates with partners of excellence that have unique experimental capabilities and immediate access to key market leaders.
Technology Developments (know-how, patents)
- CADI™ Know-how & Tools.
- TAPE patent: WO/2008/093010 - December 2006.
- AB-ACCUS patent: WO/2008/093009 - December 2006.
- RIPh patent: PCT/FR2010/050796 – May 2009.
- CNS: WO/2010/029131 (psychiatric disorders)- September, 2008. Dose reduction: use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs and preclinical evaluation platform patent, filed with CEA Life Sciences.
Spin-Offs (equity, fees, royalties)
- Pherecydes-Pharma: Our first spin-off company in the fields of BioDefense and BioSecurity developed from our CADI™ outputs (TAPE, AB-ACCUS, RiPh). Pherecydes Pharma S.A. (anti-bacterial bio-agents) was incorporated and financed on December 20, 2006.
- TheraNexus: Second company spin-off project in collaboration of CEA Life Sciences led by the CEA's research team. TheraNexus is under incubation since February 1, 2011, and co-supported by CEA life Science and BMSystems to develop (WO/2010/029131 (psychiatric disorders)), our latest co-patent filed in the field of therapeutics for psychiatric disorders.
Contract Research (fees and possible royalties)
- Pharma: (confidential).
- Cosmetics: (confidential).
- Chemical Industry: (confidential).
- Energy: (Confidential):.
Consortiums / J.V. (fees, royalties)
- Synthons program: Major Industrial biotech research platform, in partnership with ARD, IBT (Industrial biotech partners (L'Oréal, Arkema, Rhodia).